Trevi Therapeutics (TRVI) earnings history
Most recent quarter
- Fiscal period
- Q2 2026
- Period end
- Jun 30, 2026
- EPS actual
- −$0.11
- EPS estimate
- −$0.11
- EPS surprise
- −0.46%
- Revenue surprise
- +0.00%
- Revenue
- $0.00
- Revenue estimate
- $0.00
- Reported
- Aug 6, 2026
Trevi Therapeutics reported Q2 2026 results on August 6, 2026. It posted a loss of $0.11 per share, level with the rounded estimate of a $0.11 loss; the source records a slight miss of 0.46%. The table shows no revenue for this or any other quarter. Compared with Q2 2025, the loss widened from $0.09 per share.
Trevi has posted a loss in all 20 quarters in the table. Losses were largest at the start of the record, $0.34 per share in Q3 2021, and narrowed through 2022. Annual losses were $0.56 per share in 2022, $0.29 in 2023, $0.47 in 2024 and $0.32 in 2025. The first half of 2026 adds up to a $0.20 loss, against $0.18 a year earlier. The smallest quarterly losses here were $0.06, in Q4 2022, Q1 2023 and Q4 2025. Trevi's result was better than the estimate in 15 of the last 20 quarters.
Trevi reported Q3 between November 6 and November 13 in each of the past five years. That points to early or mid-November 2026 for the next report. It will show how the quarterly loss compares with the range of $0.06 to $0.11 seen over the last six quarters.
Earnings history
| Period | Reported | EPS estimate | EPS actual | Surprise | Revenue | Filing |
|---|---|---|---|---|---|---|
| Q2 2026 | Aug 6, 2026 | −$0.11 | −$0.11 | −0.46% | $0.00 | SEC |
| Q1 2026 | May 5, 2026 | −$0.08 | −$0.09 | −18.89% | $0.00 | SEC |
| Q4 2025 | Mar 17, 2026 | −$0.10 | −$0.06 | +37.89% | $0.00 | SEC |
| Q3 2025 | Nov 13, 2025 | −$0.10 | −$0.08 | +18.62% | $0.00 | SEC |
| Q2 2025 | Aug 7, 2025 | −$0.10 | −$0.09 | +13.63% | $0.00 | SEC |
| Q1 2025 | May 8, 2025 | −$0.12 | −$0.09 | +26.83% | $0.00 | SEC |
| Q4 2024 | Mar 18, 2025 | −$0.13 | −$0.11 | +14.20% | $0.00 | SEC |
| Q3 2024 | Nov 6, 2024 | −$0.12 | −$0.13 | −8.79% | $0.00 | SEC |
| Q2 2024 | Aug 8, 2024 | −$0.11 | −$0.12 | −10.50% | $0.00 | SEC |
| Q1 2024 | May 7, 2024 | −$0.09 | −$0.11 | −26.00% | $0.00 | SEC |
| Q4 2023 | Mar 20, 2024 | −$0.09 | −$0.08 | +12.76% | $0.00 | SEC |
| Q3 2023 | Nov 9, 2023 | −$0.09 | −$0.08 | +12.76% | $0.00 | SEC |
| Q2 2023 | Aug 10, 2023 | −$0.09 | −$0.07 | +17.65% | $0.00 | SEC |
| Q1 2023 | May 11, 2023 | −$0.07 | −$0.06 | +18.81% | $0.00 | SEC |
| Q4 2022 | Mar 16, 2023 | −$0.11 | −$0.06 | +43.40% | $0.00 | SEC |
| Q3 2022 | Nov 10, 2022 | −$0.13 | −$0.12 | +7.69% | $0.00 | SEC |
| Q2 2022 | Aug 11, 2022 | −$0.17 | −$0.14 | +18.84% | $0.00 | SEC |
| Q1 2022 | May 12, 2022 | −$0.26 | −$0.24 | +8.85% | $0.00 | SEC |
| Q4 2021 | Mar 17, 2022 | −$0.30 | −$0.28 | +5.08% | $0.00 | SEC |
| Q3 2021 | Nov 10, 2021 | −$0.40 | −$0.34 | +13.92% | $0.00 | SEC |
Quarterly revenue
Frequently asked questions
When did Trevi Therapeutics (TRVI) last report earnings?
Trevi Therapeutics last reported on Aug 6, 2026, covering fiscal Q2 2026.
Did TRVI beat earnings estimates?
No. Trevi Therapeutics reported EPS of −$0.11 for Q2 2026 against a −$0.11 estimate — a 0.46% miss.
Earnings figures may be restated, revised or corrected by the issuer. Past results do not indicate future performance.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.